ScreenerHero

GUTS Fractyl Health, Inc.

NAS · US · Healthcare · Biotechnology · fractyl.com
4.520USD-1.09%Mkt Cap: 59.96M $P/E: —

Fractyl Health, Inc., a metabolic therapeutics company, develops therapies for the treatment of type 2 diabetes (T2D) and obesity. It develops Revita DMR System (Revita), an outpatient procedural therapy designed to dura…

Industry Peers

Biotechnology
Screen all
VRTX
Vertex Pharmaceuticals Incorporated
$128.08BUSDP/E 29.4
MRNA
Moderna, Inc.
$78.44BUSD
REGN
Regeneron Pharmaceuticals, Inc.
$76.40BUSDP/E 18.4
ARGX
argenx SE
$57.03BUSDP/E 37.3
ARGX
argenx SE
$58.08BUSDP/E 35.4
UCB
UCB SA
$42.24BUSDP/E 18.0
RVMD
Revolution Medicines, Inc.
$43.05BUSD
ONC
BeOne Medicines AG
$41.41BUSDP/E 65.1
RPRX
Royalty Pharma plc
$32.80BUSDP/E 30.2
ALNY
Alnylam Pharmaceuticals, Inc.
$30.03BUSDP/E 37.8
ROIV
Roivant Sciences Ltd.
$25.10BUSD
BNTX
BioNTech SE
$23.93BUSD
INCY
Incyte Corporation
$22.99BUSDP/E 14.5
GMAB
Genmab A/S
$22.27BUSDP/E 30.7
GMAB
Genmab A/S
$22.54BUSDP/E 28.9
INSM
Insmed Incorporated
$22.22BUSD
ASND
Ascendis Pharma A/S
$15.03BUSDP/E 17.5
JAZZ
Jazz Pharmaceuticals plc
$15.01BUSDP/E 15.8
EXEL
Exelixis, Inc.
$14.48BUSDP/E 18.4
SMMT
Summit Therapeutics Inc.
$14.32BUSD

Key Statistics

Company
Market Cap59.96M USD
Enterprise Value74.22M USD
Revenue (TTM)—
Gross Profit0 USD
Net Income (TTM)-140.95M USD
Revenue/Share—
Last Price4.520 USD
Fiscal Year EndDec 2025
MR QuarterJun 2026
Employees100
CountryUS
SectorHealthcare
IndustryBiotechnology
ISIN—
Valuation
P/E (Trailing)—
P/E (Forward)-0.96
PEG—
EV/EBITDA-0.88
EV/Revenue—
P/S—
P/B-457.00
EPS (TTM)-10.54
EPS (Forward)-4.78
52W Range
4.3301% of range29.34
52W High29.34 USD
52W Low4.330 USD
Profitability
Gross Margin0.00%
Oper. Margin0.00%
EBITDA Margin0.00%
Profit Margin0.00%
ROE-1490.32%
ROA-116.11%
Growth
Revenue Growth—
Earnings Growth—
Cash Flow & Leverage
Operating CF-90.33M USD
CapEx (TTM)557.00K USD
FCF Margin—
FCF Yield-80.65%
Net Debt13.60M USD
Net Debt/EBITDA-0.16
Balance Sheet
Debt/Equity6.52
Current Ratio3.15
Quick Ratio3.00
Book Value/Sh-0.01 USD
Cash/Share3.55 USD
Dividends
Fwd Div Rate—
Trail. Div Rate0.00 USD
Div. Yield0.00%
5Y Avg Yield—
Payout Ratio—
Ex-Div Date—
Pay Date—
Splits
Last Split1:12
Split DateOct 5, 2026
Analyst Consensus
Rating1.3 (Strong Buy)
Strong BuyBuyHoldSellStr. Sell
Target (Mean)60.40 USD
Upside (mean)+1236.3%
Target Range24.00 USD – 96.00 USD
24.00+1236.3% to mean96.00
# Analysts6
Ownership
Shares Out.13.26M
Float12.14M
Insiders1.45%
Institutions51.51%
Short Interest
Short Ratio1.6d
Short % Float1.81%
Short % Out.1.69%
Shares Short224.71K
Short (prev mo.)221.69K
Technical
SMA 507.686 (-41.2%)
SMA 20010.10 (-55.3%)
Beta2.42
S&P 52W Chg16.45%
Avg Vol (30d)165.85K
Avg Vol (10d)232.61K
Technical Indicators
RSI (14)28.2
MACD-0.9047
MACD Signal-0.7536
MACD Hist.-0.1511
BB Upper8.602 USD
BB Middle6.288 USD
BB Lower3.974 USD
BB Width73.60%
ATR (14)0.6529 USD
Vol Ratio (20d)0.63x